Patent licensing agreement | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
16535
post-template-default,single,single-post,postid-16535,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Patent licensing agreement

Patent licensing agreement

Moss 24.09.2018

Gentian Diagnostics AS announces today that one of its subsidiaries has entered into an agreement to license out a non-core portfolio of patents to an undisclosed third party. Gentian will receive a lump sum of USD 750,000 to provide a fully paid up global licence for the patents. The grant of this patent licence is not expected to have any impact on the Company’s revenues going forward. The Company will recognize the revenues from this agreement in the 3rd quarter of 2018.

For further information, please contact:
Njaal Kind CFO, Gentian Diagnostics AS
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525

 

MeldingsID: 459987
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: INNSIDEINFORMASJON